Skip to main content

Table 3 Univariate survival analysis of 99 patients with extremity soft tissue sarcoma

From: The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma

  No. 5-year OS 5-year DFS 5-year LRFS 5-year DMFS
% P value % P value % P value % P value
Age (years)
  ≤ 60 74 85.9 < 0.001 77.4 0.001 89.4 0.236 84.4 0.002
  > 60 25 52.0   43.2   83.6   55.7  
Tumor size (cm)
  ≤ 5 34 87.5 0.130 78.0 0.229 96.7 0.162 84.2 0.263
  > 5 61 69.8   63.5   82.3   71.8  
Tumor depth
 Superficial 30 89.3 0.205 79.0 0.300 92.6 0.734 86.2 0.296
 Deep 69 71.9   65.8   86.2   73.2  
FNCLCC grade
 1–2 67 84.8 0.012 81.5 < 0.001 93.4 0.008 84.5 0.003
 3 32 60.2   44.8   75.3   61.4  
Resection margin
 Negative 77 80.0 0.065 73.6 0.109 93.9 0.001 78.9 0.202
 Close or Positive 19 67.4   52.6   65.1   68.0  
Chemotherapy
 No 58 80.2 0.522 73.0 0.535 86.0 0.313 84.0 0.115
 Yes 41 72.7   65.5   91.5   67.9  
Hemoglobin (g/dL)
  ≥ 12 84 76.7 0.914 68.0 0.398 87.5 0.574 76.6 0.765
  < 12 15 79.4   80.0   93.3   80.0  
CRP (mg/dL)
  ≤ 0.14 61 84.5 0.050 79.3 0.023 92.6 0.376 84.5 0.015
  > 0.14 33 69.3   57.1   84.1   66.5  
ESR (mm/h)
  ≤ 15 47 91.2 0.001 89.1 0.003 97.7 0.035 93.5 0.001
  > 15 44 69.4   57.8   80.6   67.4  
NLR
  ≤ 1.95 52 84.0 0.054 78.4 0.174 89.3 0.793 84.4 0.170
  > 1.95 45 70.2   63.0   89.0   69.9  
  1. Abbreviations: OS overall survival, DFS disease-free survival, DMFS distant metastasis-free survival, LRFS local recurrence-free survival, FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer, CRP C-reactive protein, ESR erythrocyte sedimentation rate, NLR neutrophil to lymphocyte ratio